Published in J Struct Biol on January 04, 2006
Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One (2011) 2.33
Performance of ZDOCK and ZRANK in CAPRI rounds 13-19. Proteins (2010) 1.39
Stability and binding properties of a modified thrombin binding aptamer. Biophys J (2007) 1.09
Pushing the limits of what is achievable in protein-DNA docking: benchmarking HADDOCK's performance. Nucleic Acids Res (2010) 1.04
PI2PE: protein interface/interior prediction engine. Nucleic Acids Res (2007) 0.96
Inactive and active states and supramolecular organization of GPCRs: insights from computational modeling. J Comput Aided Mol Des (2006) 0.95
Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin. Int J Mol Sci (2011) 0.93
Combining H/D exchange mass spectroscopy and computational docking reveals extended DNA-binding surface on uracil-DNA glycosylase. Nucleic Acids Res (2012) 0.90
Structural models of protein-DNA complexes based on interface prediction and docking. Curr Protein Pept Sci (2011) 0.80
Predicting protein-DNA interactions by full search computational docking. Proteins (2013) 0.77
Performance of MDockPP in CAPRI rounds 28-29 and 31-35 including the prediction of water-mediated interactions. Proteins (2016) 0.75
Molecular Mechanism of Binding between 17β-Estradiol and DNA. Comput Struct Biotechnol J (2016) 0.75
In silico screening of mutational effects on enzyme-proteic inhibitor affinity: a docking-based approach. BMC Struct Biol (2007) 0.75
Performance of ZDOCK and IRAD in CAPRI rounds 28-34. Proteins (2016) 0.75
Quantitative structure-activity relationship analysis of canonical inhibitors of serine proteases. J Comput Aided Mol Des (2008) 0.75
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell (2007) 10.13
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol (2007) 5.50
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med (2006) 3.11
Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev (2004) 2.20
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol (2003) 1.99
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer (2004) 1.65
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 1.64
Evaluation of ocular surface disorders: a new diagnostic tool based on impression cytology and confocal laser scanning microscopy. Br J Ophthalmol (2009) 1.59
Long-term effectiveness of autologous cultured limbal stem cell grafts in patients with limbal stem cell deficiency due to chemical burns. Clin Experiment Ophthalmol (2011) 1.56
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem (2005) 1.44
Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol (2007) 1.36
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol (2012) 1.34
DNA end resection by CtIP and exonuclease 1 prevents genomic instability. EMBO Rep (2010) 1.33
Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol (2009) 1.33
Msx2 and necdin combined activities are required for smooth muscle differentiation in mesoangioblast stem cells. Circ Res (2004) 1.33
A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J (2003) 1.32
Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori (2007) 1.31
High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol (2008) 1.27
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Degradation of human exonuclease 1b upon DNA synthesis inhibition. Cancer Res (2005) 1.21
Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs (2010) 1.21
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer (2009) 1.20
Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol (2006) 1.17
Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer (2005) 1.16
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol (2015) 1.14
ATR-dependent pathways control hEXO1 stability in response to stalled forks. Nucleic Acids Res (2007) 1.13
Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand (2003) 1.12
Osteosarcoma: the same old drugs or more? J Clin Oncol (2008) 1.12
Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. Mol Ther (2008) 1.12
Intrinsic phenotypic diversity of embryonic and fetal myoblasts is revealed by genome-wide gene expression analysis on purified cells. Dev Biol (2007) 1.11
MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proc Natl Acad Sci U S A (2006) 1.11
Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer (2005) 1.10
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res (2013) 1.09
Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep (2001) 1.09
Adolescents with cancer in Italy: entry into the national cooperative paediatric oncology group AIEOP trials. Eur J Cancer (2009) 1.06
Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II. Int J Radiat Oncol Biol Phys (2004) 1.05
Q-FIHC: quantification of fluorescence immunohistochemistry to analyse p63 isoforms and cell cycle phases in human limbal stem cells. Microsc Res Tech (2006) 1.04
High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation. J Pediatr Hematol Oncol (2002) 1.04
TGFbeta/BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts. J Cell Sci (2004) 1.03
Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J Cell Sci (2006) 1.02
Techniques for culture and assessment of limbal stem cell grafts. Ocul Surf (2010) 1.01
Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori (2005) 1.01
Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol (2005) 1.00
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther (2007) 1.00
Expression of VSX1 in human corneal keratocytes during differentiation into myofibroblasts in response to wound healing. Invest Ophthalmol Vis Sci (2006) 1.00
Periosteal osteosarcoma: a single-institution experience. Cancer (2010) 0.98
Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer (2011) 0.98
Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer (2012) 0.97
Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med (2013) 0.97
Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid. J Am Chem Soc (2012) 0.96
Limbal stem cell deficiency and ocular phenotype in ectrodactyly-ectodermal dysplasia-clefting syndrome caused by p63 mutations. Ophthalmology (2011) 0.96
Mismatch repair status and the response of human cells to cisplatin. Cell Cycle (2007) 0.96
Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. Sarcoma (2012) 0.95
Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? Orphanet J Rare Dis (2015) 0.95
A novel de novo missense mutation in TP63 underlying germline mosaicism in AEC syndrome: implications for recurrence risk and prenatal diagnosis. Am J Med Genet A (2012) 0.95
Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol (2008) 0.94
Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs (2015) 0.94
Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol (2006) 0.93
A deadly organometallic luminescent probe: anticancer activity of a ReI bisquinoline complex. Chemistry (2014) 0.93
Proangiogenic Tie2(+) macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease. Am J Pathol (2011) 0.93
Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells. Nucleic Acids Res (2007) 0.93
Embryonic stem-derived versus somatic neural stem cells: a comparative analysis of their developmental potential and molecular phenotype. Stem Cells (2005) 0.92
Osteosarcoma derived from donor stem cells carrying the Norrie's disease gene. N Engl J Med (2008) 0.92
Small round cell sarcomas. Semin Oncol (2009) 0.92
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. Clin Sarcoma Res (2013) 0.91
It takes two to tango: Ubiquitin and SUMO in the DNA damage response. Front Genet (2013) 0.90
Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. J Pediatr Hematol Oncol (2003) 0.90
Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. Am J Clin Oncol (2014) 0.90
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol (2003) 0.89
Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs (2007) 0.87
Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop (2007) 0.87
Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep (2003) 0.87
14-3-3 Proteins regulate exonuclease 1-dependent processing of stalled replication forks. PLoS Genet (2011) 0.87
DNA intercalating Ru(II) polypyridyl complexes as effective photosensitizers in photodynamic therapy. Chemistry (2014) 0.86
[(η(6)-Praziquantel)Cr(CO)3] derivatives with remarkable in vitro anti-schistosomal activity. Chemistry (2013) 0.86
Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation. Oncol Rep (2013) 0.86
Use processed human retina samples to assay for RNA. Retina (2010) 0.86
Sumoylation regulates EXO1 stability and processing of DNA damage. Cell Cycle (2015) 0.86
Reconstruction of a human hemicornea through natural scaffolds compatible with the growth of corneal epithelial stem cells and stromal keratocytes. Mol Vis (2009) 0.86
Proline isomerase Pin1 represses terminal differentiation and myocyte enhancer factor 2C function in skeletal muscle cells. J Biol Chem (2010) 0.85
Posterior lamellar graft preparation: a prospective review from an eye bank on current and future aspects. J Ophthalmol (2013) 0.85
14-3-3 checkpoint regulatory proteins interact specifically with DNA repair protein human exonuclease 1 (hEXO1) via a semi-conserved motif. DNA Repair (Amst) (2012) 0.85
Renal artery aneurysm: improved renal function after coil embolization. J Endovasc Ther (2002) 0.85
Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int J Cancer (2010) 0.85
Ferrocenyl derivatives of the anthelmintic praziquantel: design, synthesis, and biological evaluation. J Med Chem (2012) 0.84
High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncol (2005) 0.84
Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans. Clin Sarcoma Res (2012) 0.84
In vitro metabolic profile and in vivo antischistosomal activity studies of (η(6)-praziquantel)Cr(CO)3 derivatives. J Med Chem (2013) 0.84
Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett (2006) 0.84
Effect of postmortem interval on the graft endothelium during preservation and after transplantation for keratoconus. Cornea (2013) 0.83
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study. Pediatr Blood Cancer (2013) 0.83
Towards cancer cell-specific phototoxic organometallic rhenium(I) complexes. Dalton Trans (2014) 0.83
Osteosarcoma of the mobile spine. Spine (Phila Pa 1976) (2012) 0.83
Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. Ital Heart J (2003) 0.83